Risankizumab, mirikizumab and guselkumab (IL-23 blockers)
The newest biologics for Crohn's: how they work, how they are given, how well they work and how NICE recommends them
In short
- All three are biologics that block interleukin-23 (IL-23). Ustekinumab works on IL-23 too, but also blocks IL-12.
- Each begins with three starting doses (by drip, or for guselkumab by drip or injection), then regular injections under the skin.
- In trials, side effects were about as common as with a dummy treatment, but infections are possible and live vaccines should be avoided.
- NICE has approved all three for moderate to severe Crohn's, usually after another biologic or when anti-TNFs are unsuitable, choosing the least expensive suitable option.
- The 2025 BSG guideline added risankizumab as a suggested option; mirikizumab was not yet licensed for Crohn's when it was written.
Get help if
Call 999 or go to A&E
- You have difficulty breathing or swallowing, or swelling of your face, lips, mouth or throat. Crohn's & Colitis UK says to call 999 for breathing or swallowing problems.
Urgent GP appointment or NHS 111
- You think you have another sign of an allergic reaction, such as hives. Crohn's & Colitis UK says to contact NHS 111 straight away.
Contact your IBD team
- You have signs of infection, such as a high temperature, a cough that will not go away, a painful blistering rash or burning when you pee. Contact your GP or IBD team straight away.
In an emergency call 999. For urgent advice call 111 or use 111 online. 123
On this page
What are these medicines and how do they work?
Risankizumab, mirikizumab and guselkumab are biologics: antibodies made by living cells in a laboratory. All three stick to a protein called interleukin-23 (IL-23). Your immune system makes IL-23 to help fight infections, but it also plays a key part in long-lasting inflammation in the gut. Blocking it eases some of the inflammation behind Crohn's symptoms.1234
- Risankizumab: brand name Skyrizi. Licensed for Crohn's in people aged 16 and over.
- Mirikizumab: brand name Omvoh. Licensed for adults with Crohn's or ulcerative colitis.
- Guselkumab: brand name Tremfya. Licensed for adults with Crohn's or ulcerative colitis.1234
Ustekinumab is a close relative that blocks IL-23 and also IL-12; it has its own page in this hub.45
Who are they for, and what do NICE and the BSG say?
NICE has appraised all three for moderate to severe Crohn's. It recommends risankizumab for people aged 16 and over, and mirikizumab for adults, if an earlier biologic did not help enough, stopped helping or caused side effects you could not cope with, or if anti-TNF medicines are not an option. NICE allows guselkumab for adults when standard or biologic treatment has not worked or was not tolerated, and an anti-TNF has not worked, was not tolerated or is unsuitable.678
NICE judged that risankizumab is likely to work about as well as vedolizumab, that mirikizumab is likely to work about as well as risankizumab, and that guselkumab is likely to work about as well as risankizumab and vedolizumab, while costing the same or less. In each case it says that if several medicines would suit you, the least expensive should be used after talking through the pros and cons with you.678
The 2025 BSG guideline added risankizumab, along with the tablet upadacitinib, to the advanced medicines it suggests for settling and maintaining moderate to severe Crohn's. A published review of the guideline notes that mirikizumab was not licensed for Crohn's when the guideline was written, so it was not assessed. The review does not mention guselkumab. NICE's later appraisals of mirikizumab and guselkumab therefore fill a gap that the BSG guideline did not cover.789
How are they given?
None of these can be swallowed, because the gut would break them down. Each starts with three 'induction' doses to bring inflammation under control, then switches to injections under the skin to keep it under control.123
- Risankizumab: three drips in hospital, each taking about an hour, then injections using an on-body injector, a small device you stick to your skin that delivers the dose over about five minutes. In trials, over 9 in 10 people found it easy to use.
- Mirikizumab: three drips in hospital, then injections with pre-filled pens. For Crohn's each maintenance dose needs two injections, one straight after the other.
- Guselkumab: the first three doses can be either drips in hospital or injections under the skin, then injections with a pre-filled pen.123
Your hospital may arrange for the injections to be delivered to your home, where they are kept in the fridge. Your IBD team, or for some medicines the home delivery team, will teach you how to inject; some people have their injections in hospital instead. If injecting is difficult, ask your team about alternatives.123
How quickly do they work, and how well?
Crohn's & Colitis UK says most people who respond to risankizumab feel better within 4 to 12 weeks. For mirikizumab, improvement may start from about six weeks in Crohn's, and for guselkumab from about four weeks. Some people take longer, and some do not respond.123
Risankizumab: in the ADVANCE and MOTIVATE trials, about 4 in 10 people given risankizumab were in remission after 12 weeks, roughly double the rate with placebo. In the FORTIFY trial, people who carried on with risankizumab were more likely to stay in remission and to show improvement in the gut lining on endoscopy than those switched to placebo. In the SEQUENCE trial, risankizumab was at least as good as ustekinumab for symptom remission and better at healing the gut lining in people for whom anti-TNF treatment had not worked well enough or had caused unacceptable side effects.1101112
Mirikizumab: in one large trial of about 1,000 people, about 38 in 100 on mirikizumab reported remission at 12 weeks and also had healing on endoscopy at a year, compared with about 9 in 100 on placebo. NICE says trial evidence showed it works as well as ustekinumab.27
Guselkumab: in trials summarised by Crohn's & Colitis UK, about half of people were in remission after 12 weeks, and among people taking maintenance injections, 65 in 100 were in remission at 48 weeks compared with 14 in 100 on placebo.3
What checks will I need?
Before starting any of these, your team will check for infections that could flare up, including TB (usually with a blood test and chest X-ray), hepatitis and HIV, and ask about chickenpox, shingles and cold sores. They will check your vaccines are up to date. For mirikizumab and guselkumab you will also have liver blood tests, because some people develop changes in liver enzymes. Crohn's & Colitis UK says mirikizumab liver tests are likely to be monthly for three months and then every one to four months.123
During treatment your team will review your symptoms, side effects and how you are managing the injections, and may use blood tests, poo tests (faecal calprotectin) or endoscopy to see how well the medicine is working. You should have a full review at least once a year.134
What side effects can they cause?
In clinical trials, side effects were about as common with these medicines as with a dummy treatment. Commonly listed side effects across the three include colds, sore throats and chest or sinus infections, headache, tiredness, joint pain, rash or itching, and pain or redness where you inject. Guselkumab can also cause diarrhoea and raised liver enzymes; risankizumab can cause fungal skin infections.123
Because they alter the immune system, infections can be more frequent, more serious or slower to clear. Shingles is an uncommon side effect listed for mirikizumab and guselkumab. Serious allergic reactions are rare. Crohn's & Colitis UK says no interactions with other medicines are known for risankizumab or guselkumab, and no studies have been done for mirikizumab, so always check with a pharmacist before taking anything new.123
Vaccines, pregnancy and breastfeeding
Live vaccines should be avoided during treatment. Crohn's & Colitis UK gives different waiting times after the last dose: at least 21 weeks for risankizumab, at least 12 weeks for guselkumab, and at least three months (sometimes up to 12) for mirikizumab. The yearly flu jab, COVID-19 and pneumococcal vaccines are not live and are recommended.123
There is very little information about these medicines in human pregnancy. Animal studies did not show harm, but manufacturers advise effective contraception during treatment and for a period afterwards, and Crohn's & Colitis UK says guselkumab is generally not recommended in pregnancy. It is not known whether they pass into breast milk in meaningful amounts. If you are planning a pregnancy or find you are pregnant, talk to your IBD team before making any change, as an uncontrolled flare also carries risks.123
Sources
This article is written in our own words from these sources. Each number in the text points to one of them.
- Crohn's & Colitis UK Risankizumab Guide, Jul 2023 Read on the Crohn's & Colitis UK website: Risankizumab
- Crohn's & Colitis UK Mirikizumab Guide, Jul 2024 Read on the Crohn's & Colitis UK website: Mirikizumab
- Crohn's & Colitis UK Guselkumab Guide, Dec 2025 Read on the Crohn's & Colitis UK website: Guselkumab
- Crohn's & Colitis UK Biologic medicines and other targeted treatments Guide, Jul 2023 Read on the Crohn's & Colitis UK website: Biologic medicines and other targeted treatments
- Crohn's & Colitis UK Ustekinumab Read on the Crohn's & Colitis UK website: Ustekinumab
- NICE Risankizumab for previously treated moderately to severely active Crohn's disease (TA888) Guideline, May 2023 Read on the NICE website: Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)
- NICE Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080) Guideline, Jul 2025 Read on the NICE website: Mirikizumab for previously treated moderately to severely active Crohn's disease (TA1080)
- NICE Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095) Guideline, Aug 2025 Read on the NICE website: Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)
- Frontline Gastroenterology (via PMC) Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease Guide, Nov 2025 Read the paper: Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults - Part 1: Crohn's disease
- The Lancet Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials Study, May 2022 Read the paper: Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
- The Lancet Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY) Study, May 2022 Read the paper: Risankizumab as maintenance therapy for moderately to severely active Crohn's disease (FORTIFY)
- New England Journal of Medicine Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE) Study, Jul 2024 Read the paper: Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)